BioXcel Therapeutics Stock Price, News & Analysis (NASDAQ:BTAI) $3.74 +0.03 (+0.81%) (As of 09:51 AM ET) Add Compare Share Share Today's Range$3.69▼$3.7750-Day Range$2.32▼$5.5152-Week Range$2.23▼$34.13Volume57,757 shsAverage Volume1.90 million shsMarket Capitalization$109.47 millionP/E RatioN/ADividend YieldN/APrice Target$23.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability BioXcel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.29 Rating ScoreUpside/Downside543.5% Upside$23.88 Price TargetShort InterestHealthy25.12% of Float Sold ShortDividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.19) to ($2.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector181st out of 949 stocksPharmaceutical Preparations Industry69th out of 421 stocks 3.1 Analyst's Opinion Consensus RatingBioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.88, BioXcel Therapeutics has a forecasted upside of 543.5% from its current price of $3.71.Amount of Analyst CoverageBioXcel Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted25.12% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioXcel Therapeutics has recently decreased by 12.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for BioXcel Therapeutics is -1.13. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for BioXcel Therapeutics this week, compared to 4 articles on an average week.Search Interest25 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 39% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.80% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.86% of the stock of BioXcel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($6.19) to ($2.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioXcel Therapeutics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioXcel Therapeutics Stock (NASDAQ:BTAI)BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.Read More BTAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTAI Stock News HeadlinesNovember 16, 2023 | marketbeat.comUnlocking AI investment opportunities in healthcare (BTAI)AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.November 30, 2023 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of BioXcel Therapeutics, Inc. (BTAI)December 6, 2023 | Financial Alphas (Ad)Lithium Discovery So BIG You Can't Miss it, Even From SpaceWith the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!November 27, 2023 | msn.comBioXcel Therapeutics (BTAI) Price Target Increased by 5.88% to 14.28November 16, 2023 | finance.yahoo.comBTAI: Alignment with FDA on At-Home Study of BXCL501 in Alzheimer’s Agitation…November 16, 2023 | finance.yahoo.comBioXcel Therapeutics Third Quarter 2023 Earnings: Misses ExpectationsNovember 15, 2023 | markets.businessinsider.comBuy Rating for Bioxcel Therapeutics Supported by Positive FDA Alignment, Upcoming Trials, and Favorable Debt RenegotiationNovember 15, 2023 | finance.yahoo.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call TranscriptDecember 6, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 15, 2023 | finance.yahoo.comQ3 2023 BioXcel Therapeutics Inc Earnings CallNovember 15, 2023 | markets.businessinsider.comHold Rating for Bioxcel Therapeutics Amid Underperformance and Upcoming Clinical TrialsNovember 14, 2023 | msn.comWhy Is Dementia Focused BioXcel Therapeutics Stock Trading Lower Today?November 14, 2023 | benzinga.comRecap: BioXcel Therapeutics Q3 EarningsNovember 14, 2023 | finance.yahoo.comBioXcel Therapeutics Inc (BTAI) Reports Q3 2023 Financial Results and Strategic UpdatesNovember 14, 2023 | finance.yahoo.comBioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial ResultsNovember 9, 2023 | markets.businessinsider.comPromising Future for Bioxcel Therapeutics: Buy Rating Bolstered by BXCL701 Progress and Potential Alzheimer’s Market ExpansionNovember 8, 2023 | msn.comBioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy TrialNovember 8, 2023 | morningstar.comBioXcel Therapeutics Inc BTAINovember 8, 2023 | finance.yahoo.comBioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma PhenotypeNovember 6, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bioxcel Therapeutics (BTAI) and DarioHealth (DRIO)November 6, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bioxcel Therapeutics (BTAI) and DarioHealth (DRIO)November 6, 2023 | finance.yahoo.comBioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)November 5, 2023 | finance.yahoo.comFollowing a 60% decline over last year, recent gains may please BioXcel Therapeutics, Inc. (NASDAQ:BTAI) institutional ownersNovember 1, 2023 | markets.businessinsider.comBuy Rating for Bioxcel Therapeutics Backed by Promising Developments in IGALMI and BXCL501 DrugsOctober 31, 2023 | finance.yahoo.comBioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023October 30, 2023 | marketwatch.comBioXcel Therapeutics Shares Rise 29% After Getting J-Code for IgalmiOctober 30, 2023 | finance.yahoo.comBioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid ServicesSee More Headlines Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BTAI CUSIPN/A CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees183Year Founded2017Price Target and Rating Average Stock Price Target$23.88 High Stock Price Target$40.00 Low Stock Price Target$11.00 Potential Upside/Downside+543.5%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($7.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,760,000.00 Net Margins-17,037.44% Pretax Margin-17,037.60% Return on Equity-890.63% Return on Assets-135.10% Debt Debt-to-Equity Ratio16.52 Current Ratio2.51 Quick Ratio2.45 Sales & Book Value Annual Sales$380,000.00 Price / Sales285.77 Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book1.35Miscellaneous Outstanding Shares29,270,000Free Float18,793,000Market Cap$108.59 million OptionableNot Optionable Beta0.78 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Vimal D. Mehta Ph.D. (Age 62)Founder, CEO, President, & Director Comp: $1.76MMr. Javier Rodriguez (Age 51)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $638.88kMr. Matthew Wiley (Age 51)Senior VP & Chief Commercial Officer Comp: $620.12kMr. Richard I. Steinhart MBA (Age 66)Senior VP & CFO Comp: $404kDr. Frank D. Yocca Ph.D. (Age 67)Senior VP & Chief Scientific Officer Comp: $452.58kDr. Vincent J. O'Neill B.Sc. (Age 54)M.D., M.R.C.P., Senior VP & Chief Medical Officer Comp: $510.17kDr. Chetan D. Lathia Ph.D.Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory AffairsDr. Robert Risinger M.D.Chief Medical Officer - NeuroscienceMr. Robert Scala (Age 54)Vice President of Commercial Operations & Launch Planning Dr. Friso PostmaSenior Director of Neuroscience & Artificial intelligenceMore ExecutivesKey CompetitorsMilestone PharmaceuticalsNASDAQ:MISTOrganigramNASDAQ:OGIAssertioNASDAQ:ASRTGlycoMimeticsNASDAQ:GLYCSelecta BiosciencesNASDAQ:RNACView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 1,166,390 shares on 12/1/2023Ownership: 0.126%Creative PlanningBought 21,224 shares on 11/16/2023Ownership: 0.073%Ameriprise Financial Inc.Bought 318,910 shares on 11/15/2023Ownership: 2.283%Adage Capital Partners GP L.L.C.Sold 1,752,500 shares on 11/15/2023Ownership: 0.683%Legal & General Group PlcSold 5,069 shares on 11/15/2023Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions BTAI Stock Analysis - Frequently Asked Questions Should I buy or sell BioXcel Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares. View BTAI analyst ratings or view top-rated stocks. What is BioXcel Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued 12 month price targets for BioXcel Therapeutics' stock. Their BTAI share price targets range from $11.00 to $40.00. On average, they expect the company's stock price to reach $23.88 in the next year. This suggests a possible upside of 543.5% from the stock's current price. View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts. How have BTAI shares performed in 2023? BioXcel Therapeutics' stock was trading at $21.48 at the beginning of 2023. Since then, BTAI stock has decreased by 82.7% and is now trading at $3.71. View the best growth stocks for 2023 here. Are investors shorting BioXcel Therapeutics? BioXcel Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 5,080,000 shares, a decrease of 12.6% from the October 31st total of 5,810,000 shares. Based on an average daily volume of 3,130,000 shares, the short-interest ratio is currently 1.6 days. Approximately 25.1% of the shares of the company are short sold. View BioXcel Therapeutics' Short Interest. When is BioXcel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our BTAI earnings forecast. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its earnings results on Monday, August, 14th. The company reported ($1.83) EPS for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The company earned $0.46 million during the quarter, compared to analysts' expectations of $0.42 million. BioXcel Therapeutics had a negative trailing twelve-month return on equity of 890.63% and a negative net margin of 17,037.44%. The firm's revenue for the quarter was up 45600.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.35) earnings per share. What ETF holds BioXcel Therapeutics' stock ? iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT). When did BioXcel Therapeutics IPO? (BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are BioXcel Therapeutics' major shareholders? BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (9.23%), Ameriprise Financial Inc. (2.28%), Northern Trust Corp (0.77%), Adage Capital Partners GP L.L.C. (0.68%), Charles Schwab Investment Management Inc. (0.47%) and Bank of New York Mellon Corp (0.44%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta and Vincent O'neill. View institutional ownership trends. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BTAI) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.